We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Provention’s Teplizumab Gets Qualified Green Light from Advisory Committee
Provention’s Teplizumab Gets Qualified Green Light from Advisory Committee
Provention Bio’s teplizumab, a monoclonal antibody the FDA is reviewing for delaying or preventing type 1 diabetes, should be approved because the benefits outweigh the risks, a divided Endocrinologic and Metabolic Drugs Advisory Committee said Thursday in a 10-7 vote.